Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This article reviews over 1100 studies on novel biomarkers for acute kidney injury (AKI) in critically ill patients, highlighting their predictive, diagnostic, and management roles while identifying gaps for future clinical implementation.
The CloCeBa trial found cefazolin non‑inferior to cloxacillin for meticillin‑susceptible Staphylococcus aureus (MSSA) bacteraemia, with similar 90‑day composite outcomes and substantially lower rates of serious adverse events and acute kidn
LIBERATE‑D randomized hemodynamically stable patients with AKI to conservative vs conventional thrice‑weekly continuation of KRT; conservative discontinuation increased dialysis‑free recovery, shortened time to recovery, and reduced session